文献速递妇科

低级别浆液性卵巢癌中叶酸受体α的表达:探索新的治疗可能性

Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
PubMed 文献 · Gynecol Oncol · 2024-06-27

在89例低级别浆液性癌(LGSC)和42例卵巢浆液性交界性肿瘤(SBT)组织芯片中行叶酸受体α(FRα)免疫组化,78例LGSC行 panel 测序。36例(40%)LGSC为FRα高表达,FRα高表达与MAPK通路无 Alteration 相关(61% vs 20%,p<0.001),与生存无关联。结论认为FRα靶向治疗研究有必要,推荐生物标志物驱动治疗选择,尤其推荐对无MAPK通路 Alteration 者检测FRα。

要点

  • 89例LGSC中36例(40%)为FRα高表达(≥75%活肿瘤细胞中-强膜表达)。
  • 无MAPK通路 Alteration 的LGSC更常见FRα高表达(61% vs 20%,p<0.001)。
  • SBT中FRα高表达与高风险(微乳头)组织学和/或后续LGSC复发相关(53% vs 9%,p=0.008)。

核心结论

  • 未来有必要在LGSC患者中开展FRα靶向治疗研究。
  • 复发时FRα状态不一致提示再次检测可能获益。
  • 推荐采用生物标志物驱动的方法指导LGSC治疗选择。
  • 由于FRα高表达在缺乏MAPK通路遗传 Alteration 的肿瘤中更常见,尤其推荐该亚组检测FRα以确定mirvetuximab soravtansine治疗资格。
  • FRα高表达状态与年龄、种族或PFS/OS无关联。

研究设计与样本

  • 对89例LGSC和42例卵巢浆液性交界性肿瘤(SBT)的组织芯片行FRα免疫组化。
  • 对78例LGSC行临床肿瘤-正常 panel 测序。
  • 分析FRα高表达状态与临床病理特征及生存结局的关联。

主要发现

  • 89例LGSC中36例(40%)为FRα高表达(≥75%活肿瘤细胞呈中-强膜表达)。
  • 9例有不同时间点样本的LGSC患者中4例(44%)结果不一致,其中3例(33%)由FRα阴性转为FRα高表达。
  • 78例LGSC中45例(58%)存在MAPK通路遗传 Alteration,最常见累及KRAS(n=23)。
  • 无MAPK通路 Alteration 的LGSC较有 Alteration 者更常见FRα高表达(61% vs 20%,p<0.001)。
  • SBT中FRα高表达与高风险(微乳头)组织学和/或后续LGSC复发相关(53% vs 9%,p=0.008)。

关键数值与推荐

  • FRα高表达定义为≥75%活肿瘤细胞呈中-强膜表达。
  • 无MAPK通路 Alteration 的LGSC中FRα高表达比例为61%,有 Alteration 者为20%(p<0.001)。
  • SBT中伴高风险组织学和/或后续LGSC复发者FRα高表达比例为53%,无恶性复发的常规SBT为9%(p=0.008)。

临床怎么用

  • 作者推荐采用生物标志物驱动的方法指导LGSC治疗选择。
  • 作者尤其推荐对缺乏MAPK通路遗传 Alteration 的LGSC亚组检测FRα,以确定mirvetuximab soravtansine治疗资格。
  • 作者认为复发时FRα状态不一致提示再次检测可能获益。
  • 作者认为未来有必要在LGSC患者中开展FRα靶向治疗研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mirvetuximab soravtansine may be a potentially effective therapeutic option for ovarian low-grade serous carcinoma (LGSC), but the prevalence of folate receptor alpha (FRα) overexpression in this tumor type is unknown. We sought to characterize FRα expression in LGSC and its association with clinical and molecular features. METHODS: FRα immunohistochemistry was performed on a tissue microarray comprised of 89 LGSCs and 42 ovarian serous borderline tumors (SBTs). Clinical tumor-normal panel-based sequencing was performed on 78 LGSCs. Associations between FRα-high status and clinicopathologic characteristics and survival outcomes were examined. RESULTS: Of 89 LGSCs, 36 (40%) were FRα-high (≥75% of viable tumor cells exhibiting moderate-to-strong membranous expression). Of 9 patients with LGSC and samples from different timepoints, 4 (44%) had discordant results, with conversion from FRα-negative to FRα-high in 3 (33%) cases. There was no association between FRα-high status with age, race, or progression-free/overall survival. A MAPK pathway genetic alteration, most commonly involving KRAS (n = 23), was present in 45 (58%) LGSCs. Those lacking MAPK pathway alterations were more likely to be FRα-high compared to MAPK-altered LGSCs (61% vs 20%, p < 0.001). In SBTs, FRα-high expression was associated with high-risk (micropapillary) histology and/or subsequent LGSC recurrence compared to conventional SBTs without malignant recurrence (53% vs 9%, p = 0.008). CONCLUSIONS: Future studies of FRα-directed therapy in patients with LGSC are warranted. Discordant FRα status at recurrence suggests potential benefit for retesting. A biomarker-driven approach to direct treatment selection in LGSC is recommended. As high FRα expression is more common amongst tumors lacking MAPK pathway genetic alterations, FRα testing to determine eligibility for mirvetuximab soravtansine therapy is particularly recommended for this subgroup.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Manning-Geist BL, Sullivan MW, Zhou Q, et al. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities. Gynecol Oncol. 2024. PMID: 38941962. doi:10.1016/j.ygyno.2024.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。